Form 4: Pasithea Therapeutics Corp. CFO Receives Stock Options

Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp., was granted stock options under the company's 2023 Stock Incentive Plan.

Summary

• Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA), has been granted stock options.
• The grant, made under the company's 2023 Stock Incentive Plan, includes the right to buy 1,129,323 shares of common stock at an exercise price of $0.84 per share.
• These options are exercisable starting May 1, 2026, and expire on April 30, 2036.
• Vesting is scheduled to occur in stages: 33% after one year from the grant date, followed by equal quarterly installments over the next two years, contingent on continued service.
• Full vesting is triggered upon a Change in Control of the company.
• Options remain exercisable for three years post-termination of service, unless terminated for Cause.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation action (stock option grant) rather than a significant financial event or strategic shift.

Positives

• Grant of stock options to the CFO indicates a commitment to incentivizing key management personnel.
• The vesting schedule encourages long-term commitment and performance aligned with shareholder interests.
• The potential for accelerated vesting upon a Change in Control aligns management's interests with a potential acquisition scenario.

Negatives

• The exercise price of $0.84 is relatively close to the current market price, suggesting limited immediate intrinsic value without stock appreciation.
• The long vesting period means the full benefit of these options is deferred, subject to continued employment and company performance.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Pasithea Therapeutics Corp.
• If the company's stock price does not appreciate significantly above the exercise price, the options may not provide substantial financial benefit.
• Termination of employment before vesting dates will result in forfeiture of unvested options.

Future Outlook

The stock options are subject to a multi-year vesting schedule, with full vesting contingent upon continued service and potential Change in Control events. The ultimate financial benefit to the reporting person depends on the company's future stock performance.

Management Comments

• The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended.
• Shares underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years, provided the Reporting Person remains in continuous service.
• Shares underlying the Option will fully vest upon a Change in Control.
• All vested and exercisable shares underlying the Option may be exercised for up to three (3) years following termination of Continuous Service, other than a termination for Cause.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors, aimed at aligning executive compensation with long-term company growth and shareholder value, especially in companies like Pasithea Therapeutics Corp. that are focused on development and commercialization.

Stakeholder Impact

• Shareholders: The grant of options to the CFO aligns executive incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: The existence of a stock incentive plan signals a culture of equity participation, though this specific grant is to a named executive.
• Management: The CFO receives potential future financial upside tied to company performance and tenure.

Next Steps

• The reporting person will continue to vest in the stock options based on the outlined schedule and service conditions.
• The options may be exercised by the reporting person according to the vesting schedule and expiration date.

Key Dates

Keywords

Pasithea Therapeutics Corp., KTTA, Form 4, Stock Options, Daniel H. Schneiderman, Chief Financial Officer, Beneficial Ownership, Securities Exchange Act, Stock Incentive Plan, Vesting Schedule, Change in Control